{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:02:35Z","timestamp":1791291755447,"version":"4.1.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":947,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The duration of type 2 diabetes mellitus (T2DM) is an important determinant of diabetes severity. The EMPA-HEART CardioLink-6 trial reported significant left ventricular (LV) mass indexed to body surface area (LVMi) regression in patients treated with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin for 6 months. This exploratory sub-analysis of the same trial investigated the association between T2DM duration and LVMi regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A total of 97 individuals with T2DM and coronary artery disease (CAD) were randomly assigned to receive empagliflozin 10 mg daily or placebo. LVMi was measured at the baseline and 6 month visit using cardiac magnetic resonance imaging. The study population was divided into those with a baseline T2DM duration &amp;lt;10 years (n = 40) or \u226510 years (n = 57). A linear model adjusting for baseline values in each of the subgroups (ANCOVA) was used to assess the treatment effect of 6 month change in LVMi, LV end systolic volume indexed to body surface area, LV end diastolic volume indexed to body surface area and LV ejection fraction. Patients in the T2DM duration &amp;lt;10 years group (38 males [95.0%], median age 63 [IQR: 55 years to 70 years]) had a median T2DM duration of 4 years (IQR: 2.0 years to 7.0 years). Those in the T2DM duration \u226510 years group (52 males [91.2%], median age 65 [IQR: 57 years to 71 years]) had a median duration of 15 years (IQR: 12 years to 20 years). There was no significant difference in baseline LVMi according to T2DM duration (median 62 g\/m2 [IQR: 53.1 g\/m2 to 70.0 g\/m2] for T2DM duration &amp;lt;10 years; median 57.5 g\/m2 [IQR: 52.1 g\/m2 to 66.2 g\/m2] for T2DM duration \u226510 years; P = 0.11). Empagliflozin was associated with reductions in LVMi irrespective of duration of T2DM above and below 10 years (T2DM duration &amp;lt;10 years group, mean adjusted difference \u22122.90 g\/m2 [95% CI: \u22126.64 g\/m2 to 0.84 g\/m2]; T2DM duration \u226510 years group, mean adjusted difference \u22123.69 g\/m2 [95% CI: \u22120.14 g\/m2 to \u22127.24 g\/m2]; Pinteraction = 0.07).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the EMPA-HEART CardioLink-6 trial, empagliflozin treatment was associated with reductions in LVMi in people with T2DM and CAD irrespective of the duration of diabetes assessed categorically above and below 10 years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14357","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T01:49:05Z","timestamp":1681177745000},"page":"2134-2140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Diabetes Duration on Left Ventricular Mass Regression with Empagliflozin"],"prefix":"10.1093","volume":"10","author":[{"given":"Michael","family":"Moroney","sequence":"first","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"School of Medicine, Royal College of Surgeons in Ireland , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"School of Medicine, Royal College of Surgeons in Ireland , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[{"name":"Division of Cardiothoracic Surgery, Emory University School of Medicine , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. David","family":"Mazer","sequence":"additional","affiliation":[{"name":"Department of Anesthesia, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Anesthesiology and Pain Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Physiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Connelly","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Physiology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Cardiology, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Cardiology, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Quan","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwee","family":"Teoh","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Division of Endocrinology and Metabolism, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Li Ka Shing Knowledge Institute of St. Michael's Hospital , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Surgery, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Pharmacology and Toxicology, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Puar","sequence":"additional","affiliation":[{"name":"Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Department of Pharmacology and Toxicology, University of Toronto , Toronto, Ontario ,","place":["Canada"]},{"name":"Faculty of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"2026012114103311700_ehf214357-bib-0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the empa-heart cardiolink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"2026012114103311700_ehf214357-bib-0002","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012114103311700_ehf214357-bib-0003","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012114103311700_ehf214357-bib-0004","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012114103311700_ehf214357-bib-0005","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012114103311700_ehf214357-bib-0006","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114103311700_ehf214357-bib-0007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114103311700_ehf214357-bib-0008","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.2147\/DDDT.S69926","article-title":"Empagliflozin in the treatment of type 2 diabetes: evidence to date","volume":"9","author":"Shubrook","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026012114103311700_ehf214357-bib-0009","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"Sglt2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2026012114103311700_ehf214357-bib-0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12872-017-0663-6","article-title":"Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study","volume":"17","author":"Brown","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2026012114103311700_ehf214357-bib-0011","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1007\/s00125-014-3369-7","article-title":"Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes","volume":"57","author":"Zoungas","year":"2014","journal-title":"Diabetologia"},{"key":"2026012114103311700_ehf214357-bib-0012","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ahj.2021.10.181","article-title":"Incidence rates and predictors of microvascular and macrovascular complications in patients with type 2 diabetes: results from the longitudinal global discover study","volume":"243","author":"Arnold","year":"2022","journal-title":"Am Heart J"},{"key":"2026012114103311700_ehf214357-bib-0013","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2337\/diacare.27.3.704","article-title":"The significant effect of diabetes duration on coronary heart disease mortality: the Framingham heart study","volume":"27","author":"Fox","year":"2004","journal-title":"Diabetes Care"},{"key":"2026012114103311700_ehf214357-bib-0014","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jchf.2021.06.005","article-title":"Duration of diabetes and incident heart failure: the aric (atherosclerosis risk in communities) study","volume":"9","author":"Echouffo-Tcheugui","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2026012114103311700_ehf214357-bib-0015","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s41598-018-19229-w","article-title":"Increased left ventricular mass index is present in patients with type 2 diabetes without ischemic heart disease","volume":"8","author":"Seferovic","year":"2018","journal-title":"Sci Rep"},{"key":"2026012114103311700_ehf214357-bib-0016","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.amjcard.2008.02.082","article-title":"Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population","volume":"101","author":"Eguchi","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026012114103311700_ehf214357-bib-0017","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1161\/01.CIR.103.1.102","article-title":"Effect of type 2 diabetes mellitus on left ventricular geometry and systolic function in hypertensive subjects","volume":"103","author":"Palmieri","year":"2001","journal-title":"Circulation"},{"key":"2026012114103311700_ehf214357-bib-0018","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1007\/s00125-021-05524-1","article-title":"Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of hba(1c), disease duration and treatment intensity: results from the canvas program","volume":"64","author":"Young","year":"2021","journal-title":"Diabetologia"},{"key":"2026012114103311700_ehf214357-bib-0019","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/dom.14011","article-title":"Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analysis from the declare-timi 58 trial","volume":"22","author":"Bajaj","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026012114103311700_ehf214357-bib-0020","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2337\/dc21-1744","article-title":"Association of baseline hba1c with cardiovascular and renal outcomes: analyses from declare-timi 58","volume":"45","author":"Cahn","year":"2022","journal-title":"Diabetes Care"},{"key":"2026012114103311700_ehf214357-bib-0021","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"2026012114103311700_ehf214357-bib-0022","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"Sglt2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114103311700_ehf214357-bib-0023","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1111\/dom.14535","article-title":"Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: findings from the empa-reg outcome trial","volume":"23","author":"Vaduganathan","year":"2021","journal-title":"Diabetes Obes Metab"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2134\/65018009\/eschf_10_3_2134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2134\/65018009\/eschf_10_3_2134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:11:44Z","timestamp":1769022704000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/2134\/8304703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4,10]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14357","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,10]]},"assertion":[{"value":"2022-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}